Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 7/20 | 0.81 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243398 | 0.90 | PDE3A (1.00) | PDE3APDE10AHTR1AHTR7PDE3B | |
| SCHEMBL8273729 | 0.89 | PDE3A (0.82) | PDE3APDE10APDE3B | |
| SCHEMBL5243437 | 0.89 | PDE3A (0.82) | PDE3APDE10APDE3B | |
| SCHEMBL5242223 | 0.83 | PDE3A (0.73) | PDE3APDE10AHTR7PDE3B | |
| SCHEMBL5242098 | 0.83 | PDE3A (1.00) | PDE3APDE10AHTR1AHTR7PDE3B | |
| SCHEMBL12324453 | 0.82 | PRKDC (0.82) | PDE3A | |
| SCHEMBL4727937 | 0.82 | PDE3A (0.85) | PDE3APDE10AHTR1AHTR7PDE3B | |
| SCHEMBL5241719 | 0.81 | PDE3A (0.76) | PDE3APDE10AHTR1AHTR7PDE3B | |
| SCHEMBL1639500 | 0.81 | PDE10A (1.00) | PDE3APDE10AHTR1AADRA1DHTR7 | |
| SCHEMBL1639051 | 0.81 | PDE10A (1.00) | PDE3APDE10AHTR1AADRA1DHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773805-A1 | QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| EP-1773805-A1 | QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PDE5A, PDE4A, PDE3A | PDE3A 3/4885PDE10A 12/4885HTR1A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.